Literature DB >> 15140453

The use and acceptability of a one-on-one peer support program for Australian women with early breast cancer.

Nicole Rankin1, Philippa Williams, Cindy Davis, Afaf Girgis.   

Abstract

A population-based survey of Australian women diagnosed with early breast cancer examined the uptake and acceptability of a peer support program, the Breast Cancer Support Service (BCSS). We examined the characteristics and perceptions of women who did and did not use the BCSS. More than one-third (36%) had used the BCSS, most of whom first heard of it from hospital staff (36%) or clinicians (16%). Women perceived meeting someone else with similar experiences (53%) as the most beneficial aspect of the program and 89% said they would definitely recommend it to others. The findings suggest that uptake is related to provision of information about the BCSS. Peer support programs appear to be acceptable to both women who do and do not use the BCSS. To ensure that women can choose whether to participate in peer support programs requires strategies that encourage health professionals to provide comprehensive supportive care information.

Entities:  

Mesh:

Year:  2004        PMID: 15140453     DOI: 10.1016/S0738-3991(03)00142-3

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  3 in total

1.  Cancer support group participation in the United Kingdom: a national survey.

Authors:  Clare Stevinson; Anne Lydon; Ziv Amir
Journal:  Support Care Cancer       Date:  2010-04-28       Impact factor: 3.603

2.  Exploring kidney patients' experiences of receiving individual peer support.

Authors:  Jane Hughes; Eleri Wood; Gaynor Smith
Journal:  Health Expect       Date:  2009-08-19       Impact factor: 3.377

3.  Belonging to a peer support group enhance the quality of life and adherence rate in patients affected by breast cancer: A non-randomized controlled clinical trial.

Authors:  Afsaneh Malekpour Tehrani; Ziba Farajzadegan; Fariborz Mokarian Rajabi; Ahmad Reza Zamani
Journal:  J Res Med Sci       Date:  2011-05       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.